Bank Hapoalim BM Decreases Stock Holdings in Edwards Lifesciences Corporation $EW

Bank Hapoalim BM trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 37.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 19,150 shares of the medical research company’s stock after selling 11,250 shares during the period. Bank Hapoalim BM’s holdings in Edwards Lifesciences were worth $1,489,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $28,000. True Wealth Design LLC grew its holdings in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares during the last quarter. NewSquare Capital LLC grew its holdings in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $84.39 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The company’s fifty day moving average price is $85.12 and its 200 day moving average price is $80.57. The stock has a market capitalization of $48.97 billion, a P/E ratio of 36.38, a P/E/G ratio of 3.39 and a beta of 0.95. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on EW. BTIG Research restated a “buy” rating and set a $103.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Finally, Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.45.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 57,824 shares of company stock valued at $4,863,323 over the last quarter. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.